The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action.
Stahl
S M
SM
Clinical Neuroscience Research Center in San Diego and the Department of Psychiatry at the University of California San Diego, USA.
D000544:Alzheimer Disease / Q000188:drug therapy*; D002091:Butyrylcholinesterase; D002219:Carbamates / Q000494:pharmacology / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000077265:Donepezil; D005702:Galantamine / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007189:Indans / Q000494:pharmacology; D048448:Phenylcarbamates; D010880:Piperidines / Q000494:pharmacology; D011978:Receptors, Nicotinic / Q000187:drug effects; D000068836:Rivastigmine
D002219:Carbamates; D002800:Cholinesterase Inhibitors; D007189:Indans; D048448:Phenylcarbamates; D010880:Piperidines; D011978:Receptors, Nicotinic; D005702:Galantamine; D000077265:Donepezil; D002091:Butyrylcholinesterase; D000068836:Rivastigmine